MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in MiNK Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q1 2025
- Shares held
- 61.9K
- −1.05K (−1.7%) vs. Q1 2025
- Total value
- $460.8K
- −$83.4K (−15.3%) vs. Q1 2025
- New holders
- 3
- 5 more added
- Sold out
- 1
- 5 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $2.39M |
| Q1 2026 | 23 | $1.34M |
| Q4 2025 | 25 | $1.71M |
| Q3 2025 | 18 | $1.28M |
| Q2 2025 | 19 | $460.8K |
| Q1 2025 | 17 | $544.2K |
| Q4 2024 | 23 | $564.9K |
| Q3 2024 | 26 | $632.3K |
| Q2 2024 | 31 | $847.8K |
| Q1 2024 | 34 | $848.1K |
| Q4 2023 | 36 | $1.05M |
| Q3 2023 | 36 | $800.0K |
| Q2 2023 | 45 | $3.10M |
| Q1 2023 | 12 | $1.15M |
| Q4 2022 | 16 | $1.70M |
| Q3 2022 | 11 | $1.00M |
| Q2 2022 | 13 | $504.0K |
| Q1 2022 | 25 | $1.76M |
| Q4 2021 | 21 | $5.96M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding MiNK Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 23,744 | $177.6K | 0.00% | 00.0% | Unchanged |
| Longbow Finance SA | 16,667 | $123.1K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 11,492 | $86.0K | 0.00% | +238+2.1% | Added |
| BlackRock, Inc. | 7,421 | $54.8K | 0.00% | −1,357−15.5% | Reduced |
| Wells Fargo & Company | 849 | $6.27K | 0.00% | +1+0.1% | Added |
| Bank of America Corp | 568 | $4.20K | 0.00% | −189−25.0% | Reduced |
| Total Investment Management Inc | 500 | $3.69K | 0.00% | +500 | New |
| UBS Group AG | 284 | $2.10K | 0.00% | 00.0% | Unchanged |
| Covestor Ltd | 131 | $1.00K | 0.00% | +27+26.0% | Added |
| Advisor Group Holdings, Inc. | 120 | $883 | 0.00% | −118−49.6% | Reduced |
| Raymond James Financial Inc | 32 | $236 | 0.00% | +32 | New |
| BNP Paribas Arbitrage, SA | 26 | $192 | 0.00% | +3+13.0% | Added |
| Morgan Stanley | 22 | $163 | 0.00% | −2−8.3% | Reduced |
| Northwestern Mutual Wealth Management Co | 19 | $140 | 0.00% | +1+5.6% | Added |
| Game Plan Financial Advisors, LLC | 16 | $118 | 0.00% | 00.0% | Unchanged |
| Clearstead Advisors, LLC | 14 | $104 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 12 | $89 | 0.00% | −18−60.0% | Reduced |
| Key Financial Inc | 4 | $30 | 0.00% | +4 | New |
| Jones Financial Companies LLLP | 1 | $7 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −172−100.0% | Sold out |